You are here

Share:

Nandrolone 17 Beta-Carbonates

Primary tabs

Summary
The Eunice Kennedy Shriver National Institute of Child Health and Human Development seeks research co-development partners and/or licensees for the development and use of androgenic compounds as contraceptives and/or hormonal therapeutics.
NIH Reference Number
E-181-2004
Product Type
Keywords
  • Androgenic Compounds, Nandrolone, 19-nortestosterone, Male Contraceptive, National Institute of Child Health and Human Development, NICHD, Blye
Collaboration Opportunity
This invention is available for licensing and co-development.
Contact
Description of Technology

The available options for male contraceptives are limited. Androgens are administered as part of hormone-based male contraception and have also been used in the treatment of hypogonadism and hormone replacement therapy HRT. Many synthetic androgens require an oil-based delivery vehicle and have limited durations of action.
This technology describes androgenic compounds and pharmaceutical compositions thereof for use in a number of diseases or conditions, most notably as a potential male contraceptive, and as an androgenic agent suppressing the release of hormones such as the luteinizing hormone. Additional potential therapeutic areas include hypogonadism, osteoporosis, and anemia. 
Since 2016, NICHD has been testing the following lead compound as a male contraceptive in Phase I clinical trials:

Safety and pharmacokinetics of oral single-dose, 28 day repeat-dose, and dose escalation study of 11-MNTDC in healthy men have been conducted.  The drug was well tolerated without serious adverse events.  Daily oral dose of 11β-MNTDC for 28 days in healthy men showed markedly suppressed serum gonadotropins and T concentrations without serious adverse effects.  NICHD is planning another Phase I trial to test 11β-MNTDC via intramuscular injection. 

Researchers at the Eunice Kennedy Shriver National Institute of Child Health and Human Development are highly motivated in seeking licensing and/or collaboration partners for the development and use of androgenic compounds as contraceptives and/or hormonal therapeutics.

Potential Commercial Applications
  • Male contraceptive
  • Treatment of hormonal diseases

 

Competitive Advantages
  • Significant market need for male contraceptive
  • Clinical-stage asset
  • No adverse events in a Phase I dose-escalation study
  • Intramuscular (IM) injection

 

Inventor(s)

Richard Blye PhD, Hyun Kim

Development Stage
Publications

Nguyen, BT, et al. Acceptability of the oral hormonal male contraceptive prototype, 11β-methyl-19-nortestosterone dodecylcarbonate (11β-MNTDC), in a 28-day placebo-controlled trial [PMID 34153318]

Yuen, F, et al. Daily Oral Administration of the Novel Androgen 11β-MNTDC Markedly Suppresses Serum Gonadotropins in Healthy Men. [PMID 31976519]

Wu, S, et al. Safety and Pharmacokinetics of Single-Dose Novel Oral Androgen 11β-Methyl-19-Nortestosterone-17β-Dodecylcarbonate in Men. [PMID 30252057]

Patent Status
  • U.S. Patent Issued: U.S. Patent Number 7,820,642, Issued 26 Oct 2010
Therapeutic Area
Posted
Tuesday, September 13, 2022